Holen Sie sich die Stockscreener-App
1.28
1.59%
0.02
Handel nachbörslich:
1.28
Schlusskurs vom Vortag:
$1.26
Offen:
$1.26
24-Stunden-Volumen:
6.75M
Relative Volume:
0.37
Marktkapitalisierung:
$821.15M
Einnahmen:
$183.88M
Nettoeinkommen (Verlust:
$-85.78M
KGV:
-9.9456
EPS:
-0.1287
Netto-Cashflow:
$-110.95M
1W Leistung:
-0.78%
1M Leistung:
-17.42%
6M Leistung:
+14.29%
1J Leistung:
-13.51%
1-Tages-Spanne:
$1.25
$1.29
1-Wochen-Bereich:
$1.20
$1.305
52-Wochen-Spanne:
$1.04
$2.01
Geron Corp Stock (GERN) Company Profile
Firmenname
Geron Corp
Sektor
Branche
Telefon
(650) 473-7700
Adresse
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.28 | 808.32M | 183.88M | -85.78M | -110.95M | -0.1287 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-05-08 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-02-27 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2025-02-26 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-04-29 | Eingeleitet | TD Cowen | Buy |
| 2024-03-15 | Bestätigt | Needham | Buy |
| 2023-09-12 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-28 | Eingeleitet | Goldman | Neutral |
| 2022-10-28 | Eingeleitet | Wedbush | Outperform |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-11-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-02-18 | Fortgesetzt | B. Riley Securities | Buy |
| 2020-08-03 | Eingeleitet | Stifel | Buy |
| 2019-11-19 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-09-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-04-09 | Hochstufung | Needham | Hold → Buy |
| 2019-01-31 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-02 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-07-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2016-09-13 | Bestätigt | FBR & Co. | Outperform |
| 2016-09-13 | Bestätigt | FBR Capital | Outperform |
| 2015-12-07 | Bestätigt | Piper Jaffray | Overweight |
| 2015-04-21 | Eingeleitet | Oppenheimer | Outperform |
| 2014-06-12 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-03-12 | Herabstufung | MLV & Co | Buy → Hold |
| 2013-12-10 | Bestätigt | MLV & Co | Buy |
| 2013-12-10 | Hochstufung | Needham | Hold → Buy |
| 2013-11-08 | Bestätigt | MLV & Co | Buy |
| 2013-10-16 | Eingeleitet | MLV & Co | Buy |
| 2012-08-30 | Eingeleitet | Stifel Nicolaus | Buy |
| 2012-06-28 | Eingeleitet | Needham | Hold |
Alle ansehen
Geron Corp Aktie (GERN) Neueste Nachrichten
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga
Geron Corporation’s SWOT analysis: biotech stock faces sales headwinds - Investing.com
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo! Finance Canada
Geron Corp stock (US3741631036): new stock option grants keep hiring momentum in focus - AD HOC NEWS
Five new Geron hires receive options for 333,750 shares - Stock Titan
Shareholders of Geron Corporation Should Contact The Gross Law F - GuruFocus
GERN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Deep Track (GERN) reports 31.7M shares, 4.95% ownership (May 2026) - Stock Titan
GERN Stock Chart | GERON CORP (NASDAQ:GERN) - ChartMill
Geron reports Q1 revenue growth and updates on blood cancer drug progress. - Pluang
Geron Corporation Announces Positive Real-World Evidence Study of RYTELO® in Lower-Risk Myelodysplastic Syndromes Ahead of EHA 2026 Presentations - Quiver Quantitative
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 - ChartMill
RYTELO study: 37.5% of transfusion-dependent went 8 weeks transfusion-free - Stock Titan
Is Geron (GERN) One of the Best US Stocks Under $5 to Buy? - Insider Monkey
10 Best US Stocks Under $5 to Buy - Insider Monkey
Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Soleus group discloses 41.51M GERN shares (6.5%) — Soleus/Guy Levy - Stock Titan
A Look At Geron (GERN) Valuation After Q1 Results And Reaffirmed 2026 Guidance - Yahoo Finance
Geron Corporation (NASDAQ:GERN) Q1 2026 Earnings Call Transcript - Insider Monkey
Geron Corporation (NASDAQ:GERN): Is Breakeven Near? - Moomoo
Geron (GERN) Q1 2026 Earnings Call Transcript - AOL.com
Geron Corporation Q1 2026 Financial Results: Revenue, Net Loss, and SEC Filing Insights - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Geron Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Geron: Q1 Earnings Snapshot - theheraldreview.com
[10-Q] GERON CORP Quarterly Earnings Report - Stock Titan
Geron Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Geron Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Geron Q1 2026 shows revenue growth, stock rises - Investing.com
Geron Corp. (NASDAQ:GERN) Beats Q1 Estimates as RYTELO Sales Momentum Continues - ChartMill
Geron Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
GERON ($GERN) Releases Q1 2026 Earnings - Quiver Quantitative
$341M cash and $51.8M Q1 sales keep Geron on its 2026 path - Stock Titan
MSN Money - MSN
Geron earnings loom: Can RYTELO revenue sustain commercial momentum? By Investing.com - Investing.com Canada
Geron earnings loom: Can RYTELO revenue sustain commercial momentum? - Investing.com
Geron executives line up two healthcare investor conference talks - Stock Titan
Earnings Preview: Geron to Report Financial Results Pre-market on May 06 - 富途牛牛
GERN News | GERON CORP (NASDAQ:GERN) - ChartMill
Geron (GERN) to Release Earnings on Wednesday - MarketBeat
Geron (NASDAQ:GERN) Stock Price Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer - Insider Monkey
Geron (GERN) Receives a Buy from TD Cowen - The Globe and Mail
GERN Technical Analysis | Trend, Signals & Chart Patterns | GERON CORP (NASDAQ:GERN) - ChartMill
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026 - ChartMill
Geron sets May 6 financial update with webcast before market open - Stock Titan
GERN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Form 4Statement of changes in beneficial ownership of securities - ADVFN
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
Geron (NASDAQ:GERN) Stock Price Down 5.1%Here's What Happened - MarketBeat
Finanzdaten der Geron Corp-Aktie (GERN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):